Trial Profile

A Double-blind Placebo-controlled Phase 1 Study to Evaluate the Safety and Efficacy of MB-001 in Single and Multiple Ascending Doses in Healthy Human Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Nov 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
10 Jun 2024 According to a Tillots Pharma media release, Mage plans to complete the study in the first half of 2025.
10 Jun 2024 According to a Tillots Pharma media release, the company has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for the treatment of inflammatory bowel disease (IBD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com